Form 4: Rigel Pharma Exec Sells Shares for Tax Obligation

Rigel Pharmaceuticals' EVP, General Counsel, CCO & Corporate Secretary, Raymond J. Furey, disposed of 3,546 shares of common stock to cover tax liabilities.

Summary

• Raymond J. Furey, Executive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary of Rigel Pharmaceuticals, Inc. (RIGL), reported a transaction.
• On February 10, 2026, Mr. Furey disposed of 3,546 shares of common stock.
• The transaction was coded 'F', indicating payment of an exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise, or vesting of a security.
• The shares were disposed of at a price of $34.62 per share.
• Following this transaction, Mr. Furey directly beneficially owns 32,316 shares of Rigel Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transaction is a routine 'sell to cover' for tax purposes, which does not typically reflect a change in the executive's sentiment towards the company or its future performance.

Positives

• The transaction indicates the vesting of equity compensation for a key executive, which is a positive for executive retention and alignment with shareholder interests.

Negatives

• The disposition of shares, even for tax purposes, reduces the executive's direct ownership stake in the company.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that 'sell to cover' transactions, where executives sell a portion of their vested equity to satisfy tax obligations, are a common and routine occurrence in the biotechnology and pharmaceutical industries. These transactions are generally not interpreted as a signal of a change in the executive's confidence in the company's future prospects or a negative indicator for the stock.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine transaction and does not reflect a change in company fundamentals or executive confidence.
• Employees: No direct impact on employees.

Key Dates

Recommendation

The Form 4 filing details a routine 'sell to cover' transaction by an executive to satisfy tax obligations related to vested equity. This type of transaction does not provide new fundamental information about Rigel Pharmaceuticals' operational performance, strategic direction, or future prospects. Therefore, it does not warrant a change in investment recommendation based solely on this filing. Investors should maintain their current position and look to other filings for more substantive company updates.

Keywords

Rigel Pharmaceuticals, RIGL, Insider Trading, Form 4, Executive Compensation, Stock Sale, Tax Liability, Beneficial Ownership